Innovative Medicines Canada’s Updated Code of Ethical Practices Sets the Bar Higher
OTTAWA, ON / ACCESSWIRE / December 2, 2019 / Innovative Medicines Canada (IMC) today announced changes to its Code of Ethical Practices to ensure that the important working relationship between our industry and its external stakeholders continues to reflect the highest ethical standards.
“Trust and transparency are key to building strong, productive and mutually beneficial relationships with our partners. We have updated our Code of Ethical Practices to ensure our member companies continue to have a solid foundation on which to build trust with all stakeholders in the Canadian life science ecosystem”,said Pamela Fralick, President of Innovative Medicines Canada.
All IMC members agree to comply with Code of Ethical Practices as a condition of membership in the association.
The changes outlined below clarify the language of certain sections of the Code and also remove the potential for real or perceived conflicts of interest and/or undue influence.
The updated IMC Code will come into effect on January 1st, 2020. However, and to facilitate an orderly transition from the current rules, the changes related to Patient Support Programs and Medical Practices Activities will come into effect on July 1, 2020, while those related to sponsoring third-party conferences and congresses will come into effect on January 1, 2021.
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
For further information:
Director, Media and Public Relations
SOURCE: Innovative Medicines Canada
View source version on accesswire.com: